Literature DB >> 22607135

Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.

Sanjay H Chotirmall1, Stephen G Smith, Cedric Gunaratnam, Sonya Cosgrove, Borislav D Dimitrov, Shane J O'Neill, Brian J Harvey, Catherine M Greene, Noel G McElvaney.   

Abstract

BACKGROUND: Women with cystic fibrosis are at increased risk for mucoid conversion of Pseudomonas aeruginosa, which contributes to a sexual dichotomy in disease severity.
METHODS: We evaluated the effects of estradiol and its metabolite estriol on P. aeruginosa in vitro and in vivo and determined the effect of estradiol on disease exacerbations in women with cystic fibrosis.
RESULTS: Estradiol and estriol induced alginate production in P. aeruginosa strain 01 and in clinical isolates obtained from patients with and those without cystic fibrosis. After prolonged exposure to estradiol, P. aeruginosa adopted early mucoid morphology, whereas short-term exposure inhibited bacterial catalase activity and increased levels of hydrogen peroxide, which is potentially damaging to DNA. Consequently, a frameshift mutation was identified in mucA, a key regulator of alginate biosynthesis in P. aeruginosa. In vivo levels of estradiol correlated with infective exacerbations in women with cystic fibrosis, with the majority occurring during the follicular phase (P<0.05). A review of the Cystic Fibrosis Registry of Ireland revealed that the use of oral contraceptives was associated with a decreased need for antibiotics. Predominantly nonmucoid P. aeruginosa was isolated from sputum during exacerbations in the luteal phase (low estradiol). Increased proportions of mucoid bacteria were isolated during exacerbations occurring in the follicular phase (high estradiol), with a variable P. aeruginosa phenotype evident in vivo during the course of the menstrual cycle corresponding to fluctuating estradiol levels.
CONCLUSIONS: Estradiol and estriol induced mucoid conversion of P. aeruginosa in women with cystic fibrosis through a mutation of mucA in vitro and were associated with selectivity for mucoid isolation, increased exacerbations, and mucoid conversion in vivo. (Funded by the Molecular Medicine Ireland Clinician-Scientist Fellowship Programme.).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607135     DOI: 10.1056/NEJMoa1106126

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  50 in total

1.  Reproductive endocrinology: effects of oestradiol on CF exacerbations in women.

Authors:  Carol Wilson
Journal:  Nat Rev Endocrinol       Date:  2012-06-12       Impact factor: 43.330

Review 2.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  Reduced bone volumetric density and weak correlation between infection and bone markers in cystic fibrosis adult patients.

Authors:  D Gensburger; S Boutroy; R Chapurlat; R Nove-Josserand; S Roche; M Rabilloud; I Durieu
Journal:  Osteoporos Int       Date:  2016-05-11       Impact factor: 4.507

4.  17β-Estradiol inhibits phosphorylation of stromal interaction molecule 1 (STIM1) protein: implication for store-operated calcium entry and chronic lung diseases.

Authors:  John T Sheridan; Rodney C Gilmore; Michael J Watson; Christopher B Archer; Robert Tarran
Journal:  J Biol Chem       Date:  2013-10-10       Impact factor: 5.157

5.  Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort.

Authors:  Carli J Lehr; Aliza K Fink; Melissa Skeans; Albert Faro; Gabriela Fernandez; Elliott Dasenbrook; Maryam Valapour
Journal:  Ann Am Thorac Soc       Date:  2020-11

6.  Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry.

Authors:  Emily M Godfrey; Sheila Mody; Malaika R Schwartz; Sonya L Heltshe; Jennifer L Taylor-Cousar; Raksha Jain; Sandra Sufian; Tatiana Josephy; Moira L Aitken
Journal:  Contraception       Date:  2020-02-26       Impact factor: 3.375

7.  Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.

Authors:  Lenka Kramná; Pavel Dřevínek; Jake Lin; Michal Kulich; Ondrej Cinek
Journal:  Folia Microbiol (Praha)       Date:  2017-11-10       Impact factor: 2.099

8.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

9.  Relationship Between Estrogen Treatment and Skeletal Health in Women With Cystic Fibrosis.

Authors:  Malinda Wu; Erika L Bettermann; Neha Arora; William R Hunt; Courtney McCracken; Vin Tangpricha
Journal:  Am J Med Sci       Date:  2020-06-06       Impact factor: 2.378

10.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

Authors:  Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.